[HTML][HTML] Neoadjuvant EGFR-TKI therapy for EGFR-mutant NSCLC: a systematic review and pooled analysis of five prospective clinical trials
L Sun, YJ Guo, J Song, YR Wang, SL Zhang… - Frontiers in …, 2021 - frontiersin.org
Purpose The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer …
inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer …
[HTML][HTML] First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: a case series and review of the literature
FW Kong, WM Wang, L Liu, WB Wu, X Wang, M Zhang - Medicine, 2020 - journals.lww.com
Interventions: Immunotherapy was not covered by their health insurance and they refused
immune checkpoint inhibitors for financial reasons. In addition, a radical resection was not …
immune checkpoint inhibitors for financial reasons. In addition, a radical resection was not …
[HTML][HTML] Traditional Chinese medicine prolongs progression-free survival and enhances therapeutic effects in epidermal growth factor receptor tyrosine kinase …
M Tang, S Wang, B Zhao, W Wang, Y Zhu… - … medical journal of …, 2019 - ncbi.nlm.nih.gov
Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances
Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated …
Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated …
Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
YA Song, T Ma, XY Zhang, XS Cheng… - Cancer Cell …, 2019 - Springer
Background Lung cancer is one of the most common and deadly tumors around the world.
Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase …
Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase …
Clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer in patients who progressed after standard …
ZZ Song, LF Zhao, J Zuo, ZS Fan, L Wang… - OncoTargets and …, 2020 - Taylor & Francis
Purpose This study investigated the clinical outcomes and safety of apatinib mesylate in the
treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in patients who …
treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in patients who …
Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer …
SL Zhang, CB Han, L Sun, LT Huang, JT Ma - Radiation Oncology, 2020 - Springer
Purpose To assess the efficacy and safety of recombinant human endostatin in combination
with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in patients with locally …
with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in patients with locally …
Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study
G Yang, H Xu, L Yang, F Xu, S Zhang, Y Yang, Y Wang - Lung Cancer, 2020 - Elsevier
Objectives Apatinib showed efficacy in non-small cell lung cancer (NSCLC). We conducted
this phase II clinical study to assess the efficacy and safety of apatinib in combination with …
this phase II clinical study to assess the efficacy and safety of apatinib in combination with …
[HTML][HTML] The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
J Wang, D Huang, W Yang, Q Song, Y Jia… - Frontiers in …, 2022 - frontiersin.org
Background: As a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling
pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to …
pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to …
Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non–small-cell Lung Cancer: Study Protocol for an …
J Ma, G Pi, J Bi, Y Li, H He, Y Li, D Hu, V Verma… - Clinical Lung Cancer, 2021 - Elsevier
Brain radiotherapy (BR) is a well-recognized approach for multiple brain metastases (BMs)
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …
Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World …
W Hu, B Li, N Geng, X He, H Ge, P Wang… - International Journal of …, 2021 - Taylor & Francis
Background This study aimed to explore associations between PDL1 polymorphisms and
efficacy of apatinib for patients with previously treated advanced non–small cell lung cancer …
efficacy of apatinib for patients with previously treated advanced non–small cell lung cancer …